



ROTH Capital Partners Completes \$7.5 Million PIPE Offering for OXiGENE, Inc. (OXGN)

Client Information

OXiGENE, Inc. (OXGN) (“OXiGENE” or the “Company”) OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients (Source: Company Press Release).

Transaction Information

On March 11, 2010, OXiGENE closed the previously announced financing with institutional investors to sell 6,578,945 shares of its Common Stock and separate series of warrants to purchase Common Stock. Gross proceeds for the financing are approximately \$7,500,000. The net proceeds from the offering will be used to fund development of OXiGENE's high priority oncology programs, including its ongoing trials of ZYBRESTAT in non-small cell lung cancer (NSCLC) and of OXi4503 trials in solid tumors, as well as to continue its programs in anaplastic thyroid cancer (ATC) and in ophthalmology. ROTH Capital Partners served as sole placement agent for the offering.

ROTH Capital Partners

ROTH is a full service investment banking firm dedicated to advising public and private emerging growth companies. Headquartered in Newport Beach, California, ROTH offers a wide array of services to both corporate and institutional clients including: initial public offerings, follow-ons, mergers and acquisitions, SPACs, PIPEs, private placements, investment research and institutional sales and trading.

For recent news about ROTH and upcoming events please visit

[ROTH Press Room](#)

[ROTH Upcoming Conferences & Events](#)

The material, information and facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC (“ROTH”) and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2010.



For more information on how ROTH can help you, please contact:

Investment Banking

John Chambers
Head of Healthcare
Investment Banking
646-358-1901
jchambers@roth.com

Michael Margolis, R.Ph.

Managing Director
646-358-1902
mmargolis@roth.com

Warren Dunnivant II

Vice President
646-358-1903
wdunnivant@roth.com

Equity Capital Markets

Aaron Gurewitz
Head of Equity
Capital Markets
949-720-5703
agurewitz@roth.com

Lou Ellis

Sr. Vice President
949-720-5739
lellis@roth.com

Nazan Akdeniz

Sr. Vice President
949-720-5740
nakdeniz@roth.com